Japan, July 14 -- JAPAN-MULTINATIONAL TRIAL ORGANIZATION,CANON MEDICAL SYSTEMS CORP has got intellectual property rights for 'HUMAN DENATURED CRP-SPECIFIC NEUTRALIZING ANTIBODIES AND MEDICINES AND ANTI-INFLAMMATORY AGENTS COMPRISING SAME.' Other related details are as follows:
Application Number: JP,2022-020435
Category (FI): A61K39/395@Y,A61P29/00,A61P29/00,101,A61P19/02,A61P37/02,A61K39/395@N,C12N15/13,C07K16/18,C12N15/63@Z
Stage: PROBLEM TO BE SOLVED: To provide human denatured CRP-specific neutralizing antibodies usable for drugs such as anti-inflammatory agents.SOLUTION: The invention provides: (1) an anti-inflammatory agent comprising a human denatured CRP-specific neutralizing antibody; (2) a human denatured CRP-specific neutralizing antibody having an ability to bind to EILFEVPEVT (SEQ ID NO:2); (3) a polynucleotide comprising a nucleotide sequence encoding a human denatured CRP-specific neutralizing antibody; (4) an expression vector comprising the polynucleotide and a promoter operably linked thereto; (5) a transformed cell comprising an expression unit comprising the polynucleotide and a promoter operably linked thereto; and (6) a medicament comprising a human denatured CRP-specific neutralizing antibody having an ability to bind to EILFEVPEVT (SEQ ID NO:2).SELECTED DRAWING: Figure 1 (Grant)
Filing Date: Feb. 14, 2022
Publication Date: Aug. 25, 2022
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
